The aim of this study was to compare the effect of treatment with lamotrigine (LTG) or carbamazepine (CBZ) on health-related quality of life (HRQOL) and to demonstrate the use of the SEALS Inventory as a comparative tool in clinical trials. Two hundred and sixty patients with newly diagnosed epilepsy were randomized to 48 weeks of treatment with LTG (n = 131) or CBZ (n = 129). HRQOL was measured at baseline and weeks 4, 12, 24, and 48 using the modified Side Effect and Life Satisfaction (SEALS) Inventory-a 38-item questionnaire divided into five subscales: Worry, Temper, Cognition, Dysphoria, and Tiredness. Overall, SEALS scores in the LTG group decreased (improved) significantly from baseline (P = 0.001). The LTG group had improvement in all five subscales over the 48 weeks of the study. CBZ patients had significantly worse SEALS scores than LTG patients at week 4 (P < 0.038). There was no significant change (positive or negative) in subsequent SEALS assessments. Analysis of SEALS data by subscale showed that the the CBZ group experienced more cognitive side-effects in general and more general changes in energy levels and affect during the first 4 weeks of treatment. These changes may help explain the difference in study completion rate: LTG 65%, CBZ 51% (P = 0.018). LTG offers the patient with newly diagnosed epilepsy significant benefits of greater tolerability and better health-related quality of life compared with CBZ. The SEALS Inventory is an effective tool for use in clinical trials of AEDs; it was a better predictor of trial completion than seizure counts, and used as a covariate enabled better detection of treatment effects. In general practice, the use of the SEALS Inventory to assess HRQOL has the potential to improve quality of care for people with epilepsy.
INTRODUCTION
Health-related quality of life (HRQOL) assessments are critical to increasing our understanding of how patients live with a treatable but potentiality debilitating chronic condition. HRQOL studies in epilepsy are important because of the high potential for adverse effects from chronic anticonvulsant therapy and because the disease-related psychosocial pathology of epilepsy can be more handicapping than the seizures 1 .
Recent European HRQOL studies have provided interesting and similar results. One HRQOL survey of 696 people with epilepsy in the United Kingdom found a high incidence of depression (25%) and anxiety (39%), notwithstanding that most of the respondents were judged reasonably well-controlled 2 . Additionally, more than a third said they felt stigmatized by their disease. A larger cross-sectional survey of 5211 people with epilepsy in 15 European countries found a high incidence of side effects from antiepileptic drug (AED) therapy. Further, a large percentage of respondents stated that life with epilepsy negatively affected their self image, overall health, social activities, standard of living, plans for the future, ability to work in paid employment, and relationships with friends and family members 3 . More than half (51%) of the people surveyed felt stigmatized by their disease; of these, 18% felt highly stigmatized. Respondents with frequent seizures (≥1 per month) and seizures of more than one type were more likely to report psychosocial problems than those with less frequent seizures and those with only one type of seizure. The investigators concluded that the three keys to improved HRQOL for people with epilepsy are better seizure control, more tolerable AED therapy, and alleviation of disease-associated stigma.
We present HRQOL data from a previously published study-a 48-week randomized, double-blind comparison of lamotrigine (LTG) and carbamazepine (CBZ) that included 260 newly diagnosed patients with partial or generalized tonic-clonic seizures, or both 4 . The proportions of patients who were seizure free during the last 24 weeks of the study were virtually identical-LTG 39%, CBZ 38%-and no differences in efficacy were identified by seizure type. However, LTG was better tolerated as shown by greater patient completion. In the LTG treatment group, 65% completed the 48-week study, compared with 51% of the CBZ group (P = 0.018). The greatest difference between groups was in the proportion of patients withdrawn for adverse events: LTG 15%, CBZ 27% (P = 0.0138). The present study evaluates one of the HRQOL measures used in the comparison of LTG and CBZ, the SEALS Inventory. The relationship between SEALS scores, seizure control, and tolerability of antiepileptic therapy is assessed.
MATERIALS AND METHODS
The SEALS Inventory HRQOL was assessed with the Side Effect and Life Satisfaction (SEALS) Inventory 5 , a modified version of a 50-item self-report questionnaire developed by Brown and Tomlinson 6 to assess the interaction of chronic anticonvulsant therapy and psychosocial functioning. The SEALS Inventory comprises 38 questions chosen from factor analysis of data from 923 subjects. The 38 questions are grouped in five subscales: Worry, Temper, Cognition, Dysphoria, and Tiredness. Each item is scored on a 4-point system (0 = never, 1 = occasionally, 2 = sometimes, 3 = many times). The score for each subscale is the point total for the items in that subscale, and total SEALS score is the sum of the scores of the five subscales. Lower scores indicate fewer symptoms and therefore a higher HRQOL. Missing values were imputed from the average of the other response scores within the specific subscale.
Data collection
The design, conduct, and clinical outcomes of this 48-week study have been previously reported 3 . Newly diagnosed patients were randomized at screen to treatment with either CBZ (n = 129) or LTG (n = 131). Patients completed the SEALS Inventory at baseline and at weeks 4, 12, 24, and 48.
Data analysis
Simple summary statistics were calculated by visit for patients who completed the study and by time of dropout for those who withdrew early. The data were analysed using a repeated measures approach developed specifically for data that may be affected by dropout rates 7 . This approach allows estimation of treatment differences adjusted for any dropout effect, and a significance test can be performed to assess the null hypothesis that results are not affected by dropout rate.
SEALS scores were the dependent variable with covariates of time, treatment, and log baseline seizure count. Time was included as a categorical variable with five levels-weeks 0, 4, 12, 24 and 48-to provide dropout-adjusted estimates of SEALS scores. A maximum likelihood approach was used to estimate the treatment effect and other parameters of interest.
For the SEALS subscales, mean scores for each treatment group were calculated at each visit, after using last observation carried forward as a crude method of accounting for the patients who withdrew from the trial.
To determine the effect of baseline SEALS scores on the interpretation of the main endpoint in the trial, withdrawal from the study, a survival analysis using the proportional hazards model was carried out. In the original report of this trial 3 , this analysis was performed using treatment and baseline seizure count as covariates. The analysis presented here uses the baseline SEALS score as a covariate, in addition to the other two variables.
All data analyses were carried out with SAS software, predominantly using the interactive matrix language 8 .
RESULTS
Summary statistics for SEALS scores in both treatment groups are shown in Table 1 . Patients in both groups who completed the study appear to have had lower (better) SEALS scores at screen than patients who dropped out. Of patients who completed the study, mean SEALS scores in the LTG group decreased (improved) by four points over the course of the study. The interpretation of the significance of this, however, depends on consideration of the dropout data. Changes in SEALS score over the 48 weeks of the trial Figure 1 shows change in SEALS score from baseline, estimated by repeated measures analysis and adjusted for the effect of dropouts. There were significant changes in score within both groups over time. Patients randomized to LTG had significantly higher (worse) SEALS scores at baseline than patients in the CBZ group (P = 0.021). Over the duration of the trial, SEALS scores in the LTG group improved significantly from baseline (P < 0.001), but with no significant change between any of the on treatment visits (P = 0.88). On average, patients in the CBZ group had significantly worse SEALS scores at week 4 than at baseline (P = 0.038), but at subsequent assessments, no significant change from baseline was observed (P = 0.394).
SEALS subscales
Patients taking LTG showed improvement on all five subscales, over the 48-week trial. The biggest improvement appeared to be in the Cognition subscale. Overall, patients randomized to CBZ showed deterioration in the Cognition, Dysphoria, and Tiredness subscales. Improvements observed among CBZ patients in the Temper and Worry subscales were smaller than those observed in the LTG patients.
Relationship between SEALS scores and dropouts
In both treatment groups, patients who completed the full 48 weeks of therapy had lower (better) baseline SEALS scores than patients who dropped out. Dropouts also appeared to have worsening SEALS scores at the visits leading up to withdrawal. A repeated measures model was used to test whether worsening SEALS scores were associated with an in- creased likelihood of dropping out; the resulting Pvalue was 0.00017, indicating a strong positive relationship.
Withdrawal rates differed between treatment groups (P = 0.018) and are shown in Fig. 2 . Patients taking CBZ were significantly more likely to drop out. Results of the analysis of withdrawal data, taking account of baseline SEALS scores, are shown in Table 2 . The use of baseline SEALS scores increased our ability to predict patient withdrawal (P = 0.0024). The hazard ratio associated with each treatment term estimates the risk of dropping out at any time in the CBZ group, compared with the LTG group. In the analysis ignoring the SEALS scores, it appeared that CBZ patients had a 60% greater risk than LTG patients of dropping out at any time. However, when SEALS scores were added to the model, the risk of withdrawal increased to 82%.
DISCUSSION
Research has shown that HRQOL assessments have the potential to improve the quality of care in chronic diseases and conditions. Unfortunately, such assessments are not routinely part of a clinical study, nor are they routinely used in the practical management of epilepsy. This is unfortunate not only for the patient whose day-to-day experience of epilepsy may be substantially complicated by disease-related psychosocial impairment and adverse effects of drug therapy, but also for the researcher, who does not employ a useful tool for gauging the therapeutic value of various treatment options.
In this trial, LTG was better tolerated than CBZ, as evidenced by the fact that more patients in the LTG group completed the study: 65% vs. 51% (P = 0.018) 3 . Examining adverse events alone, we found that more patients in the CBZ group withdrew due to toxicity. The most common event leading to withdrawal in either group was rash: LTG 9%, CBZ 13%; but the only event occurring with significantly greater frequency in either group was somnolence: LTG 12%, CBZ 22% (P < 0.05) 3 . When HRQOL data are considered, however, patients in the CBZ group are seen to have had more cognitive side-effects in general, as recorded by the SEALS Cognition subscale, and more general changes in energy levels and affect, as recorded by the Dysphoria and Tiredness scales during the first 4 weeks of treatment. In contrast, the LTG group had significantly improved HRQOL over the 48-week study.
Higher (worse) SEALS scores were associated with a significantly increased risk of early withdrawal. Interestingly, more patients in the LTG group completed the study, despite having higher (worse) baseline SEALS scores. This may be further evidence of the greater tolerability of LTG, but we must also consider the effect the difference might have had on time to withdrawal. To this end, withdrawal rates were recalculated to include baseline SEALS scores, and it now appears that the treatment effect, in terms of time to withdrawal, may have been larger than originally indicated. Re-analysis also demonstrated that addition of the SEALS term as a covariate increased the precision of the treatment difference estimates.
In randomized comparative trials, there is a risk of error when only those patients who complete the study are evaluated. In the present study, when patients who withdrew and had higher (worse) SEALS scores were excluded from the treatment-group means calculation, mean scores improved with each dropout. Therefore, we recommend follow-up of withdrawn patients after the randomized drug is discontinued when future studies of a similar nature are undertaken. Intent-totreat analyses can then be completed for all patients to avoid the risks associated with ignoring dropouts.
Our findings are similar to those of Steiner et al. 9 who conducted a double-blind comparison of LTG and phenytoin. In that trial, 181 newly diagnosed patients were randomized to treatment for 48 weeks. No differences were found in the proportion of seizure-free patients, but LTG was better tolerated. Patients in the LTG group had a higher incidence of rash; patients in the phenytoin group had higher rates of asthenia somnolence, and ataxia. In the LTG group, SEALS scores improved for Cognition, Tiredness, Worry, and Temper subscales, and remained stable for Dyspho-ria. In the phenytoin group, SEALS scores worsened over time for the Cognition, Dysphoria and Tiredness subscales. The resulting 4-point difference in SEALS score between groups was statistically significant (P = 0.002).
Statistically significant changes in SEALS scores, both within and between treatment groups, may be considered to be of little value without considering whether they are clinically relevant to the individual patient. However, since the SEALS Inventory is a self-report scale it is reasonable to assume that any change in score is of significance to the patient since the patient is reporting the change. This is an important point which highlights the value of self-report measures in outcome studies. Measures which may be more objective, for example seizure counts, may be harder to interpret because the impact of small but statistically significant changes on the patient is not known. A cross-sectional analysis of the present study at week 4 showed that patients with seizures had a 13-point higher (worse) SEALS score than those who were seizure free (P = 0.0011) 10 . SEALS scores also worsened among patients who reported side effects from therapy. For each additional side effect, SEALS score worsened by an average of 3.4 points (P = 0.0010). As the SEALS is a self-report measure it may be assumed that a difference of 3.4 points is both clinically and statistically significant.
We conclude that LTG offers the newly diagnosed patient with partial and/or generalized tonic-clonic seizures significant benefits of greater tolerability and better quality of life, compared with CBZ. The tolerability of LTG can be improved with respect to rash by initiating therapy at a lower dose than the dose used in the present study and then slowly titrating upward until complete or maximum seizure control is achieved.
We also make the general observation that using the SEALS Inventory in trials of new AEDs offers the researcher greater precision in the measurement of treatment effects. Clinicians who use the SEALS Inventory in their everyday practice have a tool that allows for a more sensitive evaluation of an individual patient's well-being and that offers the possibility of a better quality of care for people with epilepsy.
